Sourcebrook / Guides / FDA Form 483
FDA Form 483: what it is and where to find one
A Form 483 is the list of problems an FDA investigator hands a plant at the end of an inspection. Most are never published. Here is what one means, what follows it, and where 483s surface.
Key numbers
- 3,141cited observations in our data, from 858 inspections at 425 plants
- §211.192cited most often: investigations of discrepancies, failures (302 times)
- 273statements in SEC filings reporting a Form 483, by 70 US-listed companies since 2001
- 15business days: FDA considers a written response received within this time before deciding whether to issue a warning letter
What a Form 483 is
FDA Form 483, “Inspectional Observations”, is the list an FDA investigator hands a plant's management at the end of an inspection when they have observed conditions that, in their judgment, may violate the Food, Drug and Cosmetic Act or related acts. Each observation is a short statement of what was seen, often tied to a section of the drug manufacturing rules (21 CFR Part 211). A 483 is not FDA's final decision on whether a violation occurred.
What happens after a 483
- The company responds. It can send FDA a written response with corrective actions; FDA considers a response received within 15 business days of the 483 before deciding whether to issue a warning letter.
- FDA classifies the inspection NAI, VAI or OAI. A 483 with satisfactory corrections can end VAI; OAI means FDA will recommend regulatory or administrative action.
- An OAI can lead to a warning letter, an import alert for a plant outside the US, or other action. For a drug under FDA review, an unresolved inspection problem at a plant that makes it can be a reason for a complete response letter instead of an approval.
483, OAI and warning letter compared
| Issued by | When | Made public | |
|---|---|---|---|
| Form 483 | The FDA investigator | At the end of the inspection | Not routinely; some through FDA's FOIA reading room, or by the company |
| OAI classification | FDA, after review | After the inspection report and any response are reviewed | FDA Data Dashboard, once final |
| Warning letter | FDA | Usually after an OAI classification | FDA's warning letter pages |
The regulations cited most often
FDA's Data Dashboard lists, for many inspections, each cited regulation with a short description, though not the investigator's full text. In the 3,141 citations we hold (858 inspections at 425 plants), these sections come up most:
| Regulation | Most common description | Citations |
|---|---|---|
| 21 CFR 211.192 | Investigations of discrepancies, failures | 302 |
| 21 CFR 211.22(d) | Procedures not in writing, fully followed | 171 |
| 21 CFR 211.113(b) | Procedures for sterile drug products | 158 |
| 21 CFR 211.160(b) | Scientifically sound laboratory controls | 112 |
| 21 CFR 211.100(a) | Absence of Written Procedures | 91 |
| 21 CFR 211.110(a) | Control procedures to monitor and validate performance | 89 |
| 21 CFR 211.67(a) | Cleaning / Sanitizing / Maintenance | 81 |
| 21 CFR 211.68(b) | Computer control of master formula records | 74 |
| 21 CFR 211.25(a) | Training , Education , Experience overall | 64 |
| 21 CFR 211.160(a) | Following/documenting laboratory controls | 63 |
Part 211 is FDA's current good manufacturing practice rule for finished drugs: §211.192 covers investigating discrepancies and failures, §211.22 the quality control unit, §211.113 contamination control, §211.160 laboratory controls.
Where to find a 483
- FDA Data Dashboard: the cited regulations and short descriptions for many inspections, with the plant's FDA facility ID (FEI).
- FDA's FOIA Electronic Reading Room: selected 483s posted in full, often with redactions.
- A FOIA request to FDA, which can take months.
- The company's own filings. US-listed companies sometimes disclose a 483 in an 8-K, 10-Q or 10-K, most often when it concerns a drug under FDA review or a plant that matters to their results.
483s in company filings
Since 2001, 70 US-listed drug companies reported a Form 483 in 273 statements in their SEC filings (164 in 10-Qs, 62 in 8-Ks, 47 in 6-Ks of foreign filers). 215 concern the company's own plant and 35 a contract manufacturer's. The same filings reported 191 warning letters and 165 complete response letters citing a facility. Sourcebrook quotes each statement and time-stamps it to the moment the SEC accepted the filing, then matches the plant to FDA's facility list where the text names it.
| Filed | Statements reporting a Form 483 |
|---|---|
| 2001–2005 | 22 |
| 2006–2010 | 64 |
| 2011–2015 | 82 |
| 2016–2020 | 44 |
| 2021–2026 | 61 |
How we count
Citations: FDA Data Dashboard, inspection citations, for the 425 plants Sourcebrook holds citation details for; FDA does not publish every inspection's citations. Company statements: 8-K, 10-Q, 10-K and 6-K filings on SEC EDGAR, found by full-text search and read by rules plus a language model; hand checks found 92–95 % of kept statements from 2019 on to be real inspection problems.